IRIS UniCatt

Marchetti, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.354
NA - Nord America 4.137
EU - Europa 2.592
SA - Sud America 1.028
AF - Africa 124
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 3
Totale 12.246
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.985
SG - Singapore 2.326
BR - Brasile 856
CN - Cina 622
IT - Italia 604
SE - Svezia 590
VN - Vietnam 386
FR - Francia 300
IE - Irlanda 295
DE - Germania 250
IN - India 203
ID - Indonesia 177
HK - Hong Kong 133
GB - Regno Unito 109
JP - Giappone 103
BD - Bangladesh 92
RU - Federazione Russa 85
FI - Finlandia 83
AR - Argentina 79
MX - Messico 63
CZ - Repubblica Ceca 61
CA - Canada 58
IQ - Iraq 53
NL - Olanda 50
TR - Turchia 39
KR - Corea 34
PK - Pakistan 29
AT - Austria 26
PL - Polonia 25
CO - Colombia 24
SA - Arabia Saudita 23
VE - Venezuela 23
ZA - Sudafrica 23
UA - Ucraina 22
BE - Belgio 19
ES - Italia 17
CH - Svizzera 16
CI - Costa d'Avorio 16
KE - Kenya 15
MA - Marocco 15
TN - Tunisia 15
PH - Filippine 14
AZ - Azerbaigian 13
UZ - Uzbekistan 13
EC - Ecuador 12
EG - Egitto 12
NP - Nepal 11
ET - Etiopia 10
IR - Iran 9
JO - Giordania 9
MY - Malesia 9
CL - Cile 8
IL - Israele 8
PY - Paraguay 8
UY - Uruguay 8
BG - Bulgaria 7
KZ - Kazakistan 7
CR - Costa Rica 6
LT - Lituania 6
OM - Oman 6
PE - Perù 6
TT - Trinidad e Tobago 6
AE - Emirati Arabi Uniti 5
AU - Australia 5
DZ - Algeria 5
JM - Giamaica 5
HN - Honduras 4
KG - Kirghizistan 4
KW - Kuwait 4
RO - Romania 4
SN - Senegal 4
SY - Repubblica araba siriana 4
AO - Angola 3
HU - Ungheria 3
LB - Libano 3
PA - Panama 3
PT - Portogallo 3
TJ - Tagikistan 3
AL - Albania 2
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
GY - Guiana 2
LV - Lettonia 2
NG - Nigeria 2
PS - Palestinian Territory 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AM - Armenia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
EU - Europa 1
GA - Gabon 1
Totale 12.229
Salva come PNG Salva come JPEG
Città #
Singapore 1.088
Ashburn 731
San Jose 634
Dublin 291
Chandler 256
Rome 170
Jakarta 167
Lauterbourg 159
Beijing 156
Milan 148
Los Angeles 143
New York 142
Ho Chi Minh City 132
Boston 124
Hong Kong 122
Princeton 116
Hyderabad 103
Hanoi 102
Tokyo 94
Frankfurt am Main 93
Hefei 86
São Paulo 70
Munich 61
Dallas 59
Chicago 57
Moscow 57
Helsinki 54
Washington 54
Santa Clara 52
The Dalles 47
Paris 41
Buffalo 40
Brno 38
San Mateo 37
Tukwila 37
Orem 32
Seoul 32
Rio de Janeiro 29
Boardman 26
Kent 25
Da Nang 24
Nuremberg 24
Seattle 24
Amsterdam 23
Atlanta 23
Council Bluffs 23
London 22
San Francisco 22
Marseille 20
Shanghai 19
Toronto 19
Wilmington 19
Chennai 18
Belo Horizonte 17
Brooklyn 17
Houston 17
Naples 17
Pune 17
Stockholm 17
Vienna 17
Abidjan 16
Baghdad 16
Brussels 16
Denver 16
St Louis 16
Warsaw 16
Ann Arbor 15
Brasília 15
Salt Lake City 15
Bremen 14
Dhaka 14
Mexico City 14
Turku 14
Bari 13
Bogotá 13
Campinas 13
Curitiba 13
Düsseldorf 13
Haiphong 13
Johannesburg 13
Nairobi 13
Poplar 13
Montreal 12
Tashkent 12
Baku 11
Brdo 11
Porto Alegre 11
Addis Ababa 10
Hải Dương 10
Lappeenranta 10
Manchester 10
Nanjing 10
Olomouc 10
Phoenix 10
Praia Grande 10
Salvador 10
Ankara 9
Contagem 9
Istanbul 9
Amman 8
Totale 6.800
Salva come PNG Salva come JPEG
Nome #
BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study 211
Molecular profile of brca-negative long survivor high grade serous ovarian cancer patients using a somatic multigene panel 166
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments 160
Ovarian reserve after chemotherapy in breast cancer: A systematic review and meta-analysis 155
Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance 152
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival? 142
Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach 136
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 135
BRCA testing on buccal swab to improve access to healthcare and cancer prevention: A performance evaluation 129
Tumor BRCA testing in ovarian cancer and EQA scheme: our experience of a critical evaluation 126
BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score 125
Diet and Chemotherapy: The Effects of Fasting and Ketogenic Diet on Cancer Treatment 125
Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients 123
Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850) 123
What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study 123
Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis 123
Tolerability of bevacizumab in elderly ovarian cancer patients (Turbo study): A case-control study of a real-life experience 121
Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study 117
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 116
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 113
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence 112
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer 112
Fertility preservation in patients with BRCA mutations or Lynch syndrome 111
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 108
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. 108
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study 107
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 106
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients 106
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1 104
High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment 103
Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era—Is it time for a new paradigm shift? A systematic review and meta-analysis 102
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 100
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer 100
Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study 99
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 97
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 96
Value of frozen section to tailor surgical staging in apparent early-stage epithelial ovarian cancer 93
Letrozole in the management of advanced ovarian cancer: An old drug as a new targeted therapy 93
Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer 92
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery 92
Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact 91
Pembrolizumab for advanced cervical cancer: safety and efficacy 91
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 88
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond 86
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer 85
Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer 84
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 84
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status 83
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 83
BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study 81
Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic 80
Vaginectomy: a minimally invasive treatment for cervical cancer vaginal recurrence 80
Targeted drug delivery via folate receptors in recurrent ovarian cancer: A review 79
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 78
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 78
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 77
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 77
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients 75
A commentary on the discrepancy between blood and tumour BRCA testing: An open question 75
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies 74
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes 74
Bilateral Risk-Reduction Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Meta-analysis 74
Beyond the beyond: First case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: Case report 72
Fertility preservation in gynaecologic cancers 72
Vulvo-vaginal reconstruction after radical excision for treatment of vulvar cancer: Evaluation of feasibility and morbidity of different surgical techniques 71
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 70
The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis 67
Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis 67
Ixabepilone for the treatment of endometrial cancer 67
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors 66
Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study 65
Midtrimester isolated short femur and perinatal outcomes: A systematic review and meta-analysis 65
The INCH trial - Induction chemotherapy in patients with bulky anal canal cancer: Evaluation of the pilot phase 65
Dualistic classification of epithelial ovarian cancer: Surgical and survival outcomes in a large retrospective series 65
Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing 64
Update on fertility-sparing treatment in primary and recurrent endometrial cancer 64
Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation 63
Bartholin gland cancer 63
Radiation effects on male fertility 63
Nonabsorbable suture granuloma mimicking ovarian cancer recurrence at combined positron emission tomography/computed tomography evaluation: A case report 63
Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations 62
Combined Plasma Fibrinogen and Neutrophil Lymphocyte Ratio in Ovarian Cancer Prognosis May Play a Role? 62
Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: Case report and literature review 62
Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling 61
Cediranib in ovarian cancer: state of the art and future perspectives 61
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors 60
Secondary cytoreductive surgery: Surgical approach to bulky aortic nodes, splenic metastases and mesenteric disease 60
First-line treatment of women with advanced ovarian cancer: Focus on bevacizumab 60
Threatened abortion and late-pregnancy complications: A case-control study and review of literature 60
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review 59
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression 59
Vulvodynia: Current opinion and treatment strategies 58
Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis 57
Perivascular epithelioid cell neoplasm (PEComa) of the uterus: A systematic review 57
Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms 56
Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: Feasibility, compliance, and complications 56
Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials 56
Response to: Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers 56
Immune check-point in endometrial cancer 56
Late aortic lymphocele and residual ovary syndrome after gynecological surgery 56
Totale 8.905
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.572
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022480 17 3 3 23 5 8 14 46 11 27 146 177
2022/20231.358 200 190 113 97 84 192 90 93 148 37 73 41
2023/20241.582 35 337 77 203 87 258 134 43 24 66 172 146
2024/20252.634 61 53 223 74 149 91 74 83 483 328 540 475
2025/20266.306 1.089 154 368 659 1.000 358 1.145 312 401 421 279 120
Totale 12.515